CN103536614A - Composition containing soybean phospholipid - Google Patents
Composition containing soybean phospholipid Download PDFInfo
- Publication number
- CN103536614A CN103536614A CN201310482614.3A CN201310482614A CN103536614A CN 103536614 A CN103536614 A CN 103536614A CN 201310482614 A CN201310482614 A CN 201310482614A CN 103536614 A CN103536614 A CN 103536614A
- Authority
- CN
- China
- Prior art keywords
- soybean phospholipid
- liver
- effect
- composition containing
- containing soybean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition containing soybean phospholipid. The composition is prepared from soybean phospholipid and geniposide which are taken as main materials. The composition possesses exact curative effect on liver injury; effect is achieved quickly; treatment course is short; cost is low; and side effect is low.
Description
Technical field
The invention belongs to biomedicine field, be specifically related to a kind of compositions that contains soybean phospholipid.
Background technology
In China, the hepatopath who causes because of factors such as chemicals, pathogen or excessive consumptions of alcohol has exceeded ten million, and hepatitis is one of main illness of serious threat China people's health.Hepatitis is the general name of liver generation inflammatory lesion, in the clinical treatment of hepatitis, generally adopts Synthetic therapy, i.e. antiviral agents, immunostimulant and hepatoprotective partner treatment.Antiviral agents, immunostimulant focus on the virus of removing in body, and hepatoprotective focuses on the recovery of liver.Real at present effectively antiviral agents is very few, as anti-hepatic-B virus medicines such as lamivudine, famciclovirs, also cannot suppress virus completely.The generally acknowledged effective immunostimulant of anti-hepatitis virus is interferon at present, also cannot overcome viral knock-on problem.Therefore in the treatment of viral hepatitis, antiviral agents, immunostimulant and hepatoprotective are all very important, especially need hepatic in the treatment of the damaging hepatitis of chemical toxicant, so the market of hepatoprotective is huge.
At present, very active to the research of Chinese herbal medicine anti-liver injury both at home and abroad, the effective monomer that has Chinese herbal folk, Chinese herb compound and extract from Chinese herbal medicine of domestic research.
1. Chinese herbal folk
The people such as Wang Yaojun study and find that Cordyceps has liver-protective effect, can prevent hepatocyte spotty necrosis and focal necrosis, suppress the formation of liver pseudolobuli.The Radix Astragali can make rat liver fibrosis degree obviously reduce, and reduces I, III, the deposition of IV Collagen Type VI in liver.Radix Salviae Miltiorrhizae is a kind of up-and-coming anti-liver injury Chinese medicine, and its mechanism of action is many-sided, as improves microcirculation in liver, suppresses lipid peroxidation, protection hepatocyte, the collagen degradation of promotion deposition and heavily absorption etc.Radix Notoginseng has the effect of activating blood circulation to dissipate blood stasis, can suppress fibroblastic activity in liver, reduces the generation of collagen fiber.In addition, acting on of the anti-liver injury of the Chinese medicine such as Radix Glycyrrhizae, Poria, Fructus Schisandrae Chinensis, Radix Bupleuri, Flos Carthami, Herba Sedi, Herba Silybi mariani also obtained confirmation in experimentation.
2. Chinese herb compound
Except classical compound preparation, outside Herba Sidae Rhombifoliae soup, TAOHONG SIWU TANG etc., in conjunction with theory of Chinese medical science, effective single medicinal material reasonable combination, form new compound preparation, can improve the effect of anti-liver injury.Wang Baoen etc. form activating blood circulation to dissipate blood stasis prescription by Radix Salviae Miltiorrhizae, the Radix Astragali, Caulis Spatholobi, can obviously prevent CCl
4the formation of institute's liver fibrosis due regulating liver-QI sclerosis.The prescription being comprised of Radix Codonopsis, the Radix Astragali, Fructus Jujubae has the effect of righting tonify deficiency, can alleviate hepatocellular degeneration necrosis, suppresses the formation of hepatocyte proliferation of fibrous tissue and pseudolobuli, and liver cirrhosis is had to certain preventive and therapeutic effect.
3. the effective monomer extracting in Chinese herbal medicine
Have oleanolic acid and the Cucurbitacin B of early research pass through protection hepatocyte, reduce and stimulate, and indirectly suppress startup and the development of hepatic fibrosis.Glycyrrhizin can obviously suppress the formation of liver cirrhosis.The researchs such as Chen Zhong show that ligustrazine can obviously reduce the content of rat blood serum glutamate pyruvate transaminase, malonaldehyde, III procollagen type and hepatic tissue malonaldehyde, improve the activity of superoxide dismutase in hepatic tissue.Tetrandrine is a kind of bisbenzylisoquinoline alkaloid extracting from Radix Stephaniae Tetrandrae root piece, and the effect of its anti-liver injury is confirmed.Oxymatrine is a kind of alkaloid extracting from plant Radix Sophorae Tonkinensis, and chronic hepatitis C is had to good therapeutic effect, and cultured cell in vitro research finds that oxymatrine on rat liver Ito cell proliferation has inhibitory action.
Along with the continuous change of living standards of the people and life style, various Chinese medicine liver-protecting products arise at the historic moment, but majority all exists the shortcomings such as effect is unsatisfactory, does not have so far liver-protecting product of great satisfaction.
Summary of the invention
The object of the present invention is to provide a kind of compositions that contains soybean phospholipid, said composition has auxiliary protection function to chemical liver injury.
For achieving the above object, the present invention is to be that primary raw material preparation obtains by soybean phospholipid, jasminoidin, and the weight proportion of soybean phospholipid, jasminoidin is 5: 1.
The present composition, basic upper at mentioned component, directly or again adds suitable edible or pharmaceutic adjuvant, can make the various dosage forms such as capsule, tablet, granule.The above-mentioned edible or pharmaceutic adjuvant that can add comprises: diluent, suspending agent, disintegrating agent, antioxidant, emulsifying agent, adhesive and antiseptic.
The specific embodiment
Embodiment 1: the compositions that contains soybean phospholipid, and its raw material and weight portion are: 100 parts of soybean phospholipids, 20 parts of jasminoidins, add appropriate amount of auxiliary materials, make capsule, tablet, granule etc.
Embodiment 2: to CCl
4the protective effect of induced mice chemical liver injury
By tested mice random packet, 10 every group, successive administration 7 days, 1 hour subcutaneous injection 0.5%CCl after last administration
4oil solvent 0.1mg/kg carries out copying of acute hepatic injury model, posterior orbit venous plexus blood sampling in 16 hours, separation of serum, the content of mensuration serum alt, AST.Administration is respectively organized to indicator and model group and do T-test check.
The protective effect of table 1. pair CC` induced mice chemical liver injury
With the comparison of blank group,
#p<0.05; With model control group comparison,
*p<0.05
Test shows, each administration group serum AST, ALT value are starkly lower than model control group, and close to blank group, show that said composition has definite curative effect to polytype hepatic injury, and has the features such as effective fast, short treating period, cost are low.
Claims (2)
1. the compositions that contains soybean phospholipid, is characterized by: it is to be that primary raw material preparation obtains by soybean phospholipid, jasminoidin.
2. a kind of compositions that contains soybean phospholipid according to claim 1, is characterized by: the weight proportion of soybean phospholipid, jasminoidin is 5: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310482614.3A CN103536614A (en) | 2013-10-14 | 2013-10-14 | Composition containing soybean phospholipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310482614.3A CN103536614A (en) | 2013-10-14 | 2013-10-14 | Composition containing soybean phospholipid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103536614A true CN103536614A (en) | 2014-01-29 |
Family
ID=49960728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310482614.3A Pending CN103536614A (en) | 2013-10-14 | 2013-10-14 | Composition containing soybean phospholipid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103536614A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104984353A (en) * | 2014-11-18 | 2015-10-21 | 浙江工业大学 | Geniposide phospholipid complex solid dispersion and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688501A (en) * | 2012-06-20 | 2012-09-26 | 浙江萧山医院 | Proanthocyanidin B2 phospholipid compound, and preparation method and application thereof |
-
2013
- 2013-10-14 CN CN201310482614.3A patent/CN103536614A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688501A (en) * | 2012-06-20 | 2012-09-26 | 浙江萧山医院 | Proanthocyanidin B2 phospholipid compound, and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 付田等: "栀子京尼平苷对小鼠急性酒精性肝损伤的保护作用", 《中药药理与临床》 * |
| 康东周等: "大豆磷脂对小鼠酒精性肝损伤的保护作用", 《延边大学医学学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104984353A (en) * | 2014-11-18 | 2015-10-21 | 浙江工业大学 | Geniposide phospholipid complex solid dispersion and preparation method thereof |
| CN104984353B (en) * | 2014-11-18 | 2018-02-13 | 浙江工业大学 | A kind of Gardenoside phosphatide complexes solid dispersions and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN103330865B (en) | Medicine for curing non-alcoholic steatohepatitis and preparation method thereof | |
| CN101357184A (en) | Chinese traditional medicine for treating hepatosis and preparation method thereof | |
| CN103230435A (en) | Traditional Chinese medicine for prompting hepatocyte regeneration and preparation method of medicine | |
| CN103519185A (en) | Health care product for preventing and treating chemical liver injury | |
| CN103536614A (en) | Composition containing soybean phospholipid | |
| CN103520191A (en) | Schisandra chinensis dl-tetrahydropalmatine preparation | |
| CN103520148A (en) | Preparation for auxiliary protection against chemical liver injury | |
| CN104435977A (en) | Medicine for treating liver injuries and preparation method of medicine | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN103550239A (en) | Composition for treating liver injury | |
| CN103479835A (en) | Traditional Chinese medicine for treating liver cirrhosis | |
| CN103550238A (en) | Composition containing procyanidine | |
| CN103550235A (en) | Preparation for preventing or treating liver injury | |
| CN103550201A (en) | Schisandra chinensis preparation | |
| CN103550234A (en) | Compound oleanolic acid preparation | |
| CN103494830A (en) | Composition for treating liver injury | |
| CN103550199A (en) | Compound preparation | |
| CN103550236A (en) | Compound taurine preparation | |
| CN103550202A (en) | Compound preparation | |
| CN103520149A (en) | Preparation for auxiliary protection against chemical liver injury | |
| CN103494823A (en) | Preparation for preventing or treating liver injury | |
| CN103536590A (en) | Compound preparation | |
| CN103519186A (en) | Health food for auxiliary protection against chemical liver injury | |
| CN103519184A (en) | Health care product containing glycyrrhizic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140129 |